List of Antibodies Companies in Spain - 10

Highly specialized and customer-oriented, Certest Biotec consists of four divisions, including Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology under the VIASURE brand, and Pharma. Certest Raw Materials provides high quality solutions for developing and manufacturing your IVD assays. Our expertise in protein expresión & purification, monoclonal antibodies develoment & manufacturing and primers & probes manufacturing offer to our customers a priceless support in their challenging proyects. Certest Immunodiagnostic -Rapid Test, Turbidimetry, CLIA- is committed to providing a comprehensive portfolio of diagnostic reagents for detecting infectious diseases and different markers, covering different needs of formats, types of use, throughput, precision and time from sample to result. VIASURE offers a reliable molecular diagnostic solution, from sample to intepretation of results, covering a wide range portfolio of products and enabling laboratories to better inform clinical decissions. The objective of Certest Pharma is to contribute with its technology to obtain better therapeutic products based on RNA. It is focused on three main áreas: RNAs, Delivery and Vaccines. Additionally, the expertise of our highly qualified personnel, currently numbering over 300 employees, is at the disposal of our customers, offering development and manufacturing services for the production of their own materials.

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and other innovative biopharmaceutical solutions.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

LeadArtis is a company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®. Trimerbodies provide several advantages over conventional monoclonal antibodies, such as simultaneous multiple targeting (up to six different targets per molecule), reduced size, higher avidity for targets, and a variety of effector possibilities (immune system activation, receptor blocking, delivery of toxins or cytokines). 

 Trimerbody is a novel class of proprietary multivalent and multispecific therapeutic proteins based on specific antigen-binding domains and the unique structural and functional properties of naturally occurring collagen trimerization domains. LeadArtis’s proprietary platform allows rapid generation and production of novel biological therapeutics with potential in a wide range of human diseases. The technology was originally developed following the discovery that fully functional multivalent and multispecific antibodies could be generated by employing certain engineered collagen trimerization domains and target antigen binding domains consisting of conventional single-chain antibody fragments (scFv), single-domain antibodies or antibody mimetics. As a result, the recombinant Trimerbodies display enhanced antigen-binding capacity and are very stable. Trimerbodies, with their unique structural and functional properties, form the basis of a new generation of therapeutic molecules, which due to their small size and unique structure are ideal for the generation of novel biological drugs with multiple competitive advantages over other therapeutic molecules. LeadArtis development portfolio focusses on therapeutic areas such as immuno-oncology and inflammatory-autoimmune diseases. LeadArtis offers also licensing opportunities, offering its Trimerbody® technology to biopharmaceutical companies.

LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

SunRock is a biopharmaceutical company, developing sophisticated therapeutic antibodies under innovative formats antibodies to treat incurable cancer. SunRock, working under an open innovation system, aims to develop the different programs from early discovery to the completion of phase I clinical trials. SunRock has developed an extensive portfolio of bispecific molecules targeting CCR9 and HER3 raising high expectation among the key players of the industry.

Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. Through our Original Equipment Manufacturing (OEM) business line, we research, develop, and manufacture customized assays and biomaterials. We operate directly in 30 countries, and in more than 100 territories through distributors. Our headquarters and technology centers are located in Europe and the United States, and our workforce is more than 7,000 strong.